MHC-II Profiling Identifies 57 Bacterial Peptides in Mouse Cells

On September 29, 2026, researchers reporting in PLOS Pathogens published a study identifying 57 Francisella tularensis peptides associated with MHC-II molecules in infected mouse bone marrow-derived dendritic cells. The peptides came from 23 bacterial proteins.

The paper links cell-based profiling with animal experiments

The source is an original peer-reviewed experimental study. Its peptide-identification findings are in vitro evidence from infected mouse cells. Its immune-response and bacterial-challenge findings are animal evidence from mice.

The paper, Immunopeptidomics reveals conserved and abundant Francisella tularensis proteins as immunogenic CD4 T cell antigens in mice, reports both stages within one investigation. Here, immunopeptidomics refers to isolating MHC-II-associated peptides from infected cells and identifying them by mass spectrometry.

Those stages answer different questions: which bacterial sequences were detected, which elicited measured T-cell responses and what happened after bacterial challenge. Keeping these endpoints distinct is central to reading peptide studies by evidence level.

The screen began with infected dendritic cells

For the in vitro screen, the researchers infected mouse bone marrow-derived dendritic cells with F. tularensis live vaccine strain (LVS) or the mutant LVSΔdsbA. The mutant carried a deletion in the gene encoding disulfide oxidoreductase. The team then isolated MHC-II-bound peptides and used mass spectrometry to identify bacterial sequences.

For the animal component, candidate peptides were screened for IFN-γ responses after mice had been immunized with LVS. The researchers also evaluated a peptide vaccine in mice challenged with virulent F. tularensis FSC200.

The verified study details do not establish experiment duration or mouse group sizes. Neither should be inferred from the number of peptide identifications.

Sequence counts and immune responses are distinct findings

In the infected-cell screen, the authors reported 79 confident bacterial peptide identifications. These represented 57 non-redundant sequences grouped into 24 distinct sequence clusters across 23 proteins. The different totals describe different ways of counting the analytical dataset.

The 57 sequences therefore should not be described as 57 functionally confirmed T-cell epitopes. The animal screening supplied a separate functional result: 10 peptides were identified as immunogenic CD4+ T-cell epitopes following LVS immunization.

Within that mouse model, five epitopes were reported as dominant because responses were detected in at least 80% of immunizations. These came from FTL_1678, DacD and DnaK as well as FTL_1498 and MinD. The percentage describes response detection in the reported mouse immunizations, not a rate of protection.

In the mouse challenge experiment, the peptide vaccine induced immune responses and contributed to early control of bacterial replication after exposure to virulent F. tularensis FSC200. It did not provide complete protection.

The authors identify boundaries in coverage and detection

The paper describes two limitations of its in vitro peptide profile:

• The infection setting may change antigen presentation. Bacterial protein expression and the types of antigen-presenting cells may differ during infection in an animal. The authors therefore caution that the cell-based profile may not reproduce the in vivo spectrum.
• The analytical profile may be incomplete. The number of dendritic cells used for immunoprecipitation was a critical parameter. The authors state that improvements in sample preparation and LC-MS/MS sensitivity could reveal additional bacterial peptides.

There is also insufficient evidence here for human immune responses or clinical benefit. The reported experiments used mouse-derived cells and mice.

For research interpretation, report peptide detection, measured T-cell responses and challenge outcomes as separate endpoints. A positive result at one stage does not substitute for evidence at another.

The contribution is a more specific mouse antigen map

The authors describe the mouse T-cell screening as revealing previously unknown specificity and breadth of LVS-induced immune responses. That is the study's clearest field contribution: defined bacterial peptide sequences connected to functional testing in the same research program.

Rather than establishing a broad new consensus, the paper adds antigen-specific evidence within its experimental models. It provides a basis for follow-up antigen-validation work while preserving the distinction between an analytical identification and an immune response.

For laboratory readers, interpreting peptide identity evidence on its own terms is a useful companion to that distinction. The value of this map lies in keeping each sequence connected to the experiment that made it visible.

How CaliLean helps

Selecting an evidence category for each tularemia result brings the study into the scope of CaliLean's source-led education. For investigators working from summaries that omit uncertainty or experimental limits, the brand's reviews retain study context so the record can be inspected without turning mouse findings into personal health claims.

Explore the Research Library

Sources

1. Immunopeptidomics reveals conserved and abundant Francisella ...